Trigriluzole(Trigriluzole) - 药物靶点：EAAT2 x NMDA receptor x Nav1.5 x VGSCs_在研适应症：马查多-约瑟夫病，强迫症，脊髓小脑性共济失调10型_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Trigriluzole-Biohaven Pharmaceuticals、Troriluzole、Troriluzole-hydrochloride

+ [6]

靶点

EAAT2 x NMDA receptor x Nav1.5 x VGSCs

作用机制

EAAT2调节剂(solute carrier family 1 member 2 modulators)、NMDA receptor拮抗剂(谷氨酸[NMDA]受体复合体拮抗剂)、Nav1.5阻滞剂(V型钠通道蛋白α亚基阻滞剂)

+ [1]

治疗领域

神经系统疾病遗传病与畸形其他疾病+ [3]

在研适应症

马查多-约瑟夫病强迫症脊髓小脑性共济失调10型+ [5]

非在研适应症

阿尔茨海默症焦虑症脑转移瘤+ [3]

原研机构

Yale University

在研机构

Biohaven Pharmaceuticals, Inc.

Biohaven Pharmaceutical Holding Co. Ltd.

标新有限公司

+ [2]

非在研机构-

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评快速通道 (美国)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C15H16F3N5O4S

InChIKeyYBZSGIWIPOUSHY-UHFFFAOYSA-N

CAS号1926203-09-9

查看全部结构式(2)

关联

19

项与 Trigriluzole 相关的临床试验

NCT06552260 / Not yet recruiting早期临床1期IIT

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

This research study is studying troriluzole as a possible treatment for recurrent glioblastoma.
The name of the study drug involved in this research study is:
-Troriluzole (a tripeptide prodrug of riluzole)

开始日期2025-02-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+2]

CTR20220688 / Recruiting临床3期

一项Troriluzole ？助治疗强迫症受试者的多中心、48周、开放标签安全性研究

本研究的主要目的是在根据主方案（？BHV4157-302 和BHV4157-303 研究）定义的对OCD标准治疗（SOC）反应不佳的OCD受试者中，评价troriluzole作为辅助治疗的长期安全性和耐受性。

开始日期2023-01-31

申办/合作机构

标新有限公司

[+1]

CTR20212534 / Recruiting临床3期

一项Troriluzole用于辅助治疗强迫症的随机、双盲、安慰剂对照试验

本研究的主要目的是与安慰剂相比，基于Y-BOCS评分的变化，评价Troriluzole作为辅助治疗用于对当前OCD治疗效果不佳的OCD受试者的疗效。

开始日期2022-07-19

申办/合作机构

标新有限公司

[+1]

100 项与 Trigriluzole 相关的临床结果

登录后查看更多信息

100 项与 Trigriluzole 相关的转化医学

登录后查看更多信息

100 项与 Trigriluzole 相关的专利（医药）

登录后查看更多信息

11

项与 Trigriluzole 相关的文献（医药）

2024-08-01·Neurology and Therapy

Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis

Article

作者: Khera, Rohan ; Schmahmann, Jeremy D ; Potashman, Michele H ; L'Italien, Gilbert J ; Beiner, Melissa W ; Perlman, Susan ; Maclaine, Grant D H ; Oikonomou, Evangelos K ; Coric, Vladimir

INTRODUCTIONTraditional methods for assessing movement quality rely on subjective standardized scales and clinical expertise. This limitation creates challenges for assessing patients with spinocerebellar ataxia (SCA), in whom changes in mobility can be subtle and varied. We hypothesized that a machine learning analytic system might complement traditional clinician-rated measures of gait. Our objective was to use a video-based assessment of gait dispersion to compare the effects of troriluzole with placebo on gait quality in adults with SCA.METHODSParticipants with SCA underwent gait assessment in a phase 3, double-blind, placebo-controlled trial of troriluzole (NCT03701399). Videos were processed through a deep learning pose extraction algorithm, followed by the estimation of a novel gait stability measure, the Pose Dispersion Index, quantifying the frame-by-frame symmetry, balance, and stability during natural and tandem walk tasks. The effects of troriluzole treatment were assessed in mixed linear models, participant-level grouping, and treatment group-by-visit week interaction adjusted for age, sex, baseline modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA), and time since diagnosis.RESULTSFrom 218 randomized participants, 67 and 56 participants had interpretable videos of a tandem and natural walk attempt, respectively. At Week 48, individuals assigned to troriluzole exhibited significant (p = 0.010) improvement in tandem walk Pose Dispersion Index versus placebo {adjusted interaction coefficient: 0.584 [95% confidence interval (CI) 0.137 to 1.031]}. A similar, nonsignificant trend was observed in the natural walk assessment [coefficient: 1.198 (95% CI - 1.067 to 3.462)]. Further, lower baseline Pose Dispersion Index during the natural walk was significantly (p = 0.041) associated with a higher risk of subsequent falls [adjusted Poisson coefficient: - 0.356 [95% CI - 0.697 to - 0.014)].CONCLUSIONUsing this novel approach, troriluzole-treated subjects demonstrated improvement in gait as compared to placebo for the tandem walk. Machine learning applied to video-captured gait parameters can complement clinician-reported motor assessment in adults with SCA. The Pose Dispersion Index may enhance assessment in future research. TRIAL REGISTRATION-CLINICALTRIALS.GOV IDENTIFIERNCT03701399.

2024-03-01·JID Innovations

Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model

Article

作者: Gupta, Kajal ; Reitz, Allen B ; Sauer, John Michael ; Eddy, Kevinn ; Furmanski, Philip ; Chen, Suzie ; Silk, Ann W ; Putta, Sanjana ; Chaly, Anna ; Eddin, Mohamad Naser ; Marinaro, Christina ; Fateeva, Anna ; Zloza, Andrew ; Pelletier, Jeffrey C ; Freeman, Katie B

Previous work done by our laboratory described the use of an immunocompetent spontaneous melanoma-prone mouse model, TGS (TG-3/SKH-1), to evaluate treatment outcomes using inhibitors of glutamatergic signaling and immune checkpoint for 18 weeks. We showed a significant therapeutic efficacy with a notable sex-biased response in male mice. In this follow-up 18-week study, the dose of the glutamatergic signaling inhibitor was increased (from 1.7 mg/kg to 25 mg/kg), which resulted in improved responses in female mice but not male mice. The greatest reduction in tumor progression was observed in male mice treated with single-agent troriluzole and anti-PD-1. Furthermore, a randomly selected group of mice was removed from treatment after 18 weeks and maintained for up to an additional 48 weeks demonstrating the utility of the TGS mouse model to perform a ≥1-year preclinical therapeutic study in a physiologically relevant tumor-host environment. Digital spatial imaging analyses were performed in tumors and tumor microenvironments across treatment modalities using antibody panels for immune cell types and immune cell activation. The results suggest that immune cell populations and cytotoxic activities of T cells play critical roles in treatment responses in these mice. Examination of a group of molecular protein markers based on the proposed mechanisms of action of inhibitors of glutamatergic signaling and immune checkpoint showed that alterations in expression levels of xCT, γ-H2AX, EAAT2, PD-L1, and PD-1 are likely associated with the loss of treatment responses. These results suggest the importance of tracking changes in molecular markers associated with the mechanism of action of therapeutics over the course of a longitudinal preclinical therapeutic study in spatial and temporal manners.

2023-10-01·Journal of Investigative Dermatology

A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study

Article

作者: Isola, Allison L ; Gupta, Kajal ; Chaly, Anna ; Zloza, Andrew ; Chen, Suzie ; Eddy, Kevinn ; Shah, Raj ; Chen, Wenjin ; Reitz, Allen B ; Silk, Ann W ; Eddin, Mohamad Naser ; Campagnolo, Joseph ; Reuhl, Kenneth ; Rasheed, Maryam Abdur ; Furmanski, Philip ; Rossi, Marco ; Fateeva, Anna ; Freeman, Katie B ; Robinson, Ann K ; Pelletier, Jeffrey C ; Diaz, Jesus ; Marinaro, Christina

Mouse models that reflect human disorders provide invaluable tools for the translation of basic science discoveries to clinical therapies. However, many of these in vivo therapeutic studies are short term and do not accurately mimic patient conditions. In this study, we used a fully immunocompetent, transgenic mouse model, TGS, in which the spontaneous development of metastatic melanoma is driven by the ectopic expression of a normal neuronal receptor, mGluR1, as a model to assess longitudinal treatment response (up to 8 months) with an inhibitor of glutamatergic signaling, troriluzole, which is a prodrug of riluzole, plus an antibody against PD-1, an immune checkpoint inhibitor. Our results reveal a sex-biased treatment response that led to improved survival in troriluzole and/or anti-PD-1-treated male mice that correlated with differential CD8⁺ T cells and CD11b⁺ myeloid cell populations in the tumor-stromal interface, supporting the notion that this model is a responsive and tractable system for evaluating therapeutic regimens for melanoma in an immunocompetent setting.

60

项与 Trigriluzole 相关的新闻（医药）

2024-09-24

·Outsourcing Pharma

Biohaven’s real-world trial shows positive results for spinocerebellar ataxia drug

Biohaven, which spun out of Biohaven Pharmaceuticals in 2022 when its parent company was acquired by Pfizer, has had a number of setbacks in the development of troriluzole –a prodrug of riluzole– including a phase 3 trial failure in 2022. However, the company continued development, as results of the failed phase 3 trial showed that patients with the most common kind of spinocerebellar ataxia, known as type 3, who made up 41% of the trial group, did appear to benefit from troriluzole. In 2023, Biohaven submitted a new drug application to the FDA for troriluzole in patients with type 3 spinocerebellar ataxia, but the regulator refused to file the application based on the drugs earlier trial failure. The company then worked with the FDA to design a new, ‘real-world’ trial that compared 65 spinocerebellar ataxia patients (all types) given troriluzole to two sets of matched external controls in the US and Europe. The results announced this week show troriluzole treated patients had a 50-70% slowing of disease progression compared with the external untreated controls over 3 years of follow up. Using the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) external controls were at least 4 times more likely to have a 2 point or greater worsening of their disease than patients treated with troriluzole. "SCA is a debilitating, relentlessly progressive disease that destroys quality of life, leaving patients unable to care for themselves, walk, or speak,” said Susan Perlman, director of the ataxia clinic and neurogenetics clinical trials at the David Geffen School of Medicine at UCLA, in a press statement about the trial. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “Troriluzole is the very first treatment to show a delay in disease progression that can give patients additional years of independence, where they can walk without assistance, continue to work, play with their children, and participate in daily activities. This is an exciting and hopeful moment for the SCA community." Fighting for a treatment Spinocerebellar ataxias are a group of rare progressive, inherited neurological diseases that affect movement and result in increasing disability over time. There are many types of spinocerebellar ataxias, defined by the genetic cause, and they are estimated to affect around 150,000 people in the US. Due to the heterogeneity of genetic mutations causing this condition the symptoms vary in severity but can be fatal. Most often, patients retain mental capacity, but gradually lose physical control of movement. No cure exists for spinocerebellar ataxia and limited treatments addressing the symptoms are available, with no FDA approved therapies specifically designed for treating spinocerebellar ataxia. Riluzole is approved to treat amyotrophic lateral sclerosis (ALS) and similar motor neuron diseases and has been shown to increase survival in some patients by several months. Troriluzole is a prodrug of riluzole and may have dosing advantages and better bioavailability than riluzole. Based on the new trial results, Biohaven now plans to resubmit troriluzole to the US Food and Drug Administration (FDA) for treatment of all SCA genotypes before the end of the year. Due to the lack of treatments and rare nature of the disease, troriluzole is eligible for priority review because it has FDA orphan drug and fast-track status.

临床3期上市批准快速通道孤儿药申请上市

2024-09-24

·BioSpace

Biohaven Sets Stage for Comeback With Pivotal Study Results in Spinocerebellar Ataxia

iStock, Prostock-Studio The FDA previously refused to review Biohaven’s candidate in the indication due to a failed late-stage trial. However, the company is now planning to NDA in the fourth quarter of 2024. Biohaven on Monday unveiled topline pivotal data for its drug candidate troriluzole, touting significant symptomatic and functional improvements in patients with spinocerebellar ataxia. Troriluzole treatment led to “robust and clinically meaningful slowing of disease progression” with the investigational treatment slowing down patients’ rate of decline by 50% to 70% versus untreated comparators, according to the company, while delaying disease progression by 1.5 years to 2.2 years over the study’s three-year duration. Using the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) tool, which classifies disease progression as at least a two-point worsening in score, Biohaven found that untreated patients were more than four times more likely to progress, compared with patients on troriluzole. CEO Vlad Coric in a statement said that Biohaven’s spinocerebellar ataxia (SCA) program, which includes Monday’s pivotal study, “has provided the first evidence of a clinically meaningful treatment benefit as well as slowing disease progression in SCA patients.” “The need for treatments for this deadly neurodegenerative disease is urgent,” Coric said. “We look forward to interacting with regulatory agencies to bring troriluzole to patients with SCA.” Biohaven is gearing up for a New Drug Application (NDA) in the fourth quarter of 2024, backed by the results from Monday’s readout, as well as previous efficacy and safety data. SCA refers to a group of heritable neurodegenerative disorders that typically involve the progressive loss of voluntary control over movement. The disease class also leads to the gradual atrophy of several crucial parts of their nervous system, including cerebellum, brainstem and spinal cord. Patients suffer from compromised motor skills, often leading to falls and other related injuries. SCA can also manifest as speech impairments, difficulties swallowing and, ultimately, premature death. There are currently no approved treatments for SCA. Biohaven’s troriluzole is an investigational modulator of the glutamate neurotransmitter, which is the most abundant excitatory messenger in humans. By boosting the uptake of glutamate from the synapse, it helps lower the overall levels of the neurotransmitter in the synaptic space, preventing the over-excitation of neurons and addressing a key pathway in SCA. However, despite a promising mechanism of action, troriluzole’s development has run into several rough patches in recent years. In August 2023, the FDA refused to review Biohaven’s NDA for troriluzole, pointing out that the study used to support the application failed its primary endpoint. The biotech announced the Phase III failure in May 2022 . Troriluzole has also run into difficulties beyond SCA. In January 2021, Biohaven unveiled disappointing Alzheimer’s disease data for the drug candidate, revealing that it had failed to significantly outperform placebo at 48 weeks. Nearly a year earlier, troriluzole failed a Phase III study in generalized anxiety disorder. Still, William Blair analyst Myles Minter is optimistic about troriluzole’s chances moving forward. Minter in a note to investors said that they are “encouraged by the consistent signals of benefit … in a population with extremely limited treatment options.” The firm expects the FDA to call for an advisory committee meeting to discuss the differences between Monday’s readout and the first failed Phase III study.

临床3期申请上市

2024-09-23

·药明康德

病情恶化速度减缓高达70%，创新小分子即将递交新药申请

▎药明康德内容团队编辑 Biohaven今日宣布，在研疗法troriluzole在治疗脊髓小脑性共济失调（SCA）的关键性临床试验BHV4157-206-RWE中达到主要终点。在治疗3年后，与外部对照组相比，患者的功能性共济失调评分（f-SARA）变化获得显著改善。 BHV4157-206-RWE是在与美国FDA讨论后设计的关键性临床研究，旨在评估troriluzole在SCA患者中的疗效，以治疗3年后f-SARA变化为衡量指标。该研究利用了3期临床试验数据，并根据FDA的真实世界证据（RWE）指导，使用来自美国小脑性共济失调临床研究联盟（CRC-SCA）的未治疗SCA患者作为外部对照。多项分析的数据综合显示，在troriluzole治疗组中，SCA患者的疾病进展获得显著且具有临床意义地减缓。治疗带来的益处使得相较于未治疗的患者，病情恶化的速度减慢了50%-70%，在3年的研究期间，疾病进展延缓了1.5至2.2年。 ▲f-SARA变化表明，troriluzole减缓了SCA疾病进展（图片来源：参考资料[1]）此外，预先指定的分析还采用了来自欧洲SCA自然病程研究（EUROSCA）的独立外部对照组，用于支持全球监管申请。使用EUROSCA患者以及结合CRC-SCA和EUROSCA患者作为外部对照的综合分析结果也在所有时间点上与主要疗效分析一致，且具有统计学显著性。EUROSCA数据的加入增加了外部对照样本数量，并增强了在第1、第2和第3年troriluzole治疗差异的统计学显著性。脊髓小脑性共济失调是一组显性遗传的神经退行性疾病，其特征为自主运动控制的逐步丧失以及小脑、脑干和脊髓的萎缩。患者承受显著的疾病负担，包括需要轮椅、步态障碍导致跌倒、由于语言障碍无法交流、吞咽困难和过早死亡。目前，SCA没有FDA批准的治疗方法，也没有治愈手段。 Troriluzole的主要作用机制是减少突触中的谷氨酸水平。Troriluzole增强了位于胶质细胞上的兴奋性氨基酸的转运体表达和功能，这些转运体在清除突触中的谷氨酸方面发挥着关键作用。Troriluzole有潜力在多种与谷氨酸过量相关的疾病中得到进一步开发。Biohaven计划在2024年第四季度向FDA提交新药申请（NDA）。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA). Retrieved September 23, 2024, from https://ir.biohaven.com/news-releases/news-release-details/biohaven-achieves-positive-topline-results-pivotal-study 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期申请上市

100 项与 Trigriluzole 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Trigriluzole	-	DB15079

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
马查多-约瑟夫病	申请上市	美国	Biohaven Ltd.	2023-05-31
强迫症	临床3期	荷兰	Biohaven Pharmaceuticals, Inc.	2021-01-29
脊髓小脑性共济失调10型	临床3期	美国	Biohaven Pharmaceuticals, Inc.	2019-03-08
脊髓小脑性共济失调10型	临床3期	中国	Biohaven Pharmaceuticals, Inc.	2019-03-08
脊髓小脑性共济失调8型	临床3期	中国	Biohaven Pharmaceuticals, Inc.	2019-03-08
脊髓小脑性共济失调8型	临床3期	美国	Biohaven Pharmaceuticals, Inc.	2019-03-08
脊髓小脑性共济失调	临床3期	美国	标新有限公司	2019-03-08
焦虑症	临床前	美国	Biohaven Pharmaceutical Holding Co. Ltd.	-
广泛性焦虑障碍	药物发现	美国	Biohaven Pharmaceuticals, Inc.	2019-02-19
阿尔茨海默症	药物发现	美国	Biohaven Pharmaceuticals, Inc.	2018-07-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NEWS 人工标引	临床3期	脊髓小脑性共济失调	-	Troriluzole	(廠製築願鬱鹹獵簾淵齋) = Biohaven said that the once-daily oral drug met the primary endpoint across all genotypes of SCA included in the study and that it showed statistically significant superiority after both one and two years compared to the external control groups. 膚膚簾衊膚壓艱醖鬱鹹 (繭顧艱壓構製鹽構製觸 ) 达到更多	积极	2024-09-23
NCT03701399 (Phase III Clinical Trial of Troriluzole, AAN2024)	临床3期	脊髓小脑性共济失调	218	Troriluzole	(顧糧鏇鹽窪衊膚鹹積衊): adj. interaction coefficient = 0.58 (95% CI, 0.14 ~ 1.03)	积极	2024-04-09
				Placebo
AAN2024	N/A	-	-	Troriluzole 140mg QD	(鹹築餘蓋鹹築鹽構襯憲) = 築鏇製鹽願遞餘鏇願糧築淵製積簾糧憲憲廠範 (膚繭鑰積醖構網齋憲襯 ) 更多	-	2024-04-09
				Troriluzole 200mg QD	(鹹築餘蓋鹹築鹽構襯憲) = 壓網顧憲築廠壓廠繭淵築淵製積簾糧憲憲廠範 (膚繭鑰積醖構網齋憲襯 ) 更多
AAN2024	N/A	-	-	Troriluzole 200 mg	(鹹廠範網廠鹹願艱淵網) = values were 40% and 50% higher after troriluzole 100 mg and 280 mg, respectively vs oral riluzole 50 mg 簾憲憲範艱襯窪蓋製鬱 (醖憲醖淵艱繭艱選壓醖 ) 更多	-	2024-04-09
				Troriluzole 280 mg
NCT04899921 (CTgov)	临床2期	转移性黑色素瘤 \| 脑转移瘤	1	ipilimumab+Troriluzole+nivolumab (Ipilimumab + Nivolumab + Troriluzole [Phase I Dose Level 1])	願衊襯獵餘網淵鹽齋製(艱獵壓窪鑰蓋膚積範艱) = 餘壓衊廠觸襯壓繭選繭遞鬱壓鏇蓋糧鹹選醖窪 (選顧餘築構構夢廠憲鏇, 網構鏇壓鏇製顧襯鑰網 ~ 襯壓築網鹹鑰淵憲廠願) 更多	-	2023-12-13
				ipilimumab+Troriluzole+nivolumab (Ipilimumab + Nivolumab + Troriluzole [Phase I Dose Level 2])	願衊襯獵餘網淵鹽齋製(艱獵壓窪鑰蓋膚積範艱) = 鹽獵衊憲齋選醖醖遞糧遞鬱壓鏇蓋糧鹹選醖窪 (選顧餘築構構夢廠憲鏇, 窪遞艱蓋齋齋積鹽蓋築 ~ 膚範鬱築鑰衊獵蓋築鬱) 更多
NCT03605667 (T2 Protect AD, CTgov)	临床2期	阿尔茨海默症	350	Placebo oral capsule	鏇鑰構鹽簾範糧繭醖蓋(鬱顧蓋糧築餘願窪繭齋) = 遞蓋夢鬱艱鏇鏇艱鬱壓襯淵獵鹽廠遞廠簾積範 (廠蓋壓獵積觸齋鏇淵鹹, 餘鏇鬱繭積廠鏇餘鏇選 ~ 齋簾鬱壓鏇製衊鏇醖衊) 更多	-	2023-12-06
NCT03299166 (CTgov)	临床2/3期	强迫症	426	Troriluzole (Troriluzole - Randomization Phase)	蓋齋繭鬱窪願鏇繭淵築(壓構構蓋糧蓋憲積淵顧) = 醖餘願膚選築夢觸積遞醖襯膚壓顧鹹顧窪窪襯 (鏇衊範顧襯廠願餘醖築, 鹽膚夢觸窪糧鹽糧鹹範 ~ 鏇醖獵繭窪膚獵廠構鏇) 更多	-	2023-06-02
				placebo+troriluzole (Placebo - Randomization Phase)	蓋齋繭鬱窪願鏇繭淵築(壓構構蓋糧蓋憲積淵顧) = 鏇築積艱觸築鬱鏇繭憲醖襯膚壓顧鹹顧窪窪襯 (鏇衊範顧襯廠願餘醖築, 憲醖獵構膚蓋窪艱顧糧 ~ 網糧廠遞顧製蓋衊鬱醖) 更多
NCT03829241 (CTgov)	临床3期	广泛性焦虑障碍	881	Troriluzole (Troriluzole)	夢築廠廠衊選襯鹽艱簾(鑰積構蓋壓淵鹹鏇壓顧) = 淵積衊襯餘餘鹽範鏇鏇遞襯構繭淵觸襯鬱壓餘 (遞獵簾蓋餘壓網醖築膚, 選選製夢繭蓋齋簾襯鏇 ~ 繭鹽鑰壓餘繭製壓糧糧) 更多	-	2022-12-28
				Placebo+Troriluzole (Placebo)	夢築廠廠衊選襯鹽艱簾(鑰積構蓋壓淵鹹鏇壓顧) = 淵壓鹹遞獵觸鬱糧醖壓遞襯構繭淵觸襯鬱壓餘 (遞獵簾蓋餘壓網醖築膚, 願壓淵鬱顧淵製鏇鏇構 ~ 鏇獵獵鏇簾夢製壓憲艱) 更多
NCT03701399 (NEWS) 人工标引	临床3期	脊髓小脑性共济失调	-	troriluzole	鑰築衊齋積顧積構選齋(觸築壓遞窪夢簾壓積製) = 範願鬱憲廠蓋餘繭積鹽獵壓製遞顧鑰網廠淵鹹 (構襯顧網鏇廠獵鑰製膚 ) 更多	不佳	2022-05-23
				placebo	鑰築衊齋積顧積構選齋(觸築壓遞窪夢簾壓積製) = 餘夢觸簾獵範鹹鬱鹹製獵壓製遞顧鑰網廠淵鹹 (構襯顧網鏇廠獵鑰製膚 ) 更多
NCT02960893 (CTgov)	临床2/3期	脊髓小脑性共济失调10型 \| 马查多-约瑟夫病 \| 脊髓小脑性共济失调8型	141	Troriluzole (Troriluzole - Randomization Phase)	糧餘獵獵膚範製願醖衊(網範築壓淵蓋顧蓋遞淵) = 願顧齋構簾憲願壓齋鏇鹹製廠淵襯蓋夢襯襯壓 (繭顧壓鑰鑰糧網顧獵餘, 獵願糧窪構鏇窪餘壓簾 ~ 築觸築餘製襯遞憲積築) 更多	-	2020-08-14
				placebo (Placebo - Randomization Phase)	糧餘獵獵膚範製願醖衊(網範築壓淵蓋顧蓋遞淵) = 艱遞餘蓋構繭簾襯鹽鹹鹹製廠淵襯蓋夢襯襯壓 (繭顧壓鑰鑰糧網顧獵餘, 襯鹹獵願築憲鹽簾鏇願 ~ 壓艱衊獵夢觸淵積構壓) 更多